6-氯-1,2,3,4-四氢萘-2-胺 | 60480-00-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: 6-氯-1,2,3,4-四氢萘-2-胺
• 英文名称: 6-chloro-1,2,3,4-tetrahydro-naphthalen-2-ylamine
• 英文别名: 6-Chloro-1,2,3,4-tetrahydronaphthalen-2-amine
• CAS: 60480-00-4
• 化学式: C₁₀H₁₂ClN
• mdl: MFCD06739163
• 分子量: 181.665
• InChiKey: CJRJTCMSQLEPFQ-UHFFFAOYSA-N

物化性质

• 沸点：
  284.2±40.0 °C(Predicted)
• 密度：
  1.166±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921450090

反应信息

• 作为反应物：
  描述：

  6-氯-1,2,3,4-四氢萘-2-胺 在 盐酸 作用下， 以 乙醇 为溶剂， 以38%的产率得到6-氯-1,2,3,4-四氢萘-2-胺盐酸盐
  参考文献：
  名称：

  “Methylene Bridge” to 5-HT₃ Receptor Antagonists: Conformationally Constrained Phenylguanidines

  摘要：

  Arylguanidines, depending upon their aromatic substitution pattern, display varying actions at 5-HT3 receptors (e.g., partial agonist, agonist, superagonist). Here, we demonstrate that conformational constraint of these agents as dihydroquinazolines (such as A6CDQ; 1) results in their conversion to 5-HT3 receptor antagonists. We examined the structure activity relationships of 1. Replacement/removal of any of the guanidinium nitrogen atoms of 1 resulted in decreased affinity. All three nitrogen atoms of 1 are necessary for optimal binding affinity at 5-HT3 receptors. Introduction of substituents as small as an N2-methyl group abolishes affinity. The results are consistent with homology modeling/docking studies and binding data from site-directed mutagenesis studies. Introducing a "methylene bridge" to the arylguanidine structure, regardless of its functional activity, results in a 5-HT3 receptor antagonist.

  DOI：

  10.1021/acschemneuro.8b00431
• 作为产物：
  描述：

  6-氯-3,4-二氢-2(1H)-萘酮 在 ammonium acetate 、 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 反应 37.0h， 以0.11 g的产率得到6-氯-1,2,3,4-四氢萘-2-胺
  参考文献：
  名称：

  “Methylene Bridge” to 5-HT₃ Receptor Antagonists: Conformationally Constrained Phenylguanidines

  摘要：

  Arylguanidines, depending upon their aromatic substitution pattern, display varying actions at 5-HT3 receptors (e.g., partial agonist, agonist, superagonist). Here, we demonstrate that conformational constraint of these agents as dihydroquinazolines (such as A6CDQ; 1) results in their conversion to 5-HT3 receptor antagonists. We examined the structure activity relationships of 1. Replacement/removal of any of the guanidinium nitrogen atoms of 1 resulted in decreased affinity. All three nitrogen atoms of 1 are necessary for optimal binding affinity at 5-HT3 receptors. Introduction of substituents as small as an N2-methyl group abolishes affinity. The results are consistent with homology modeling/docking studies and binding data from site-directed mutagenesis studies. Introducing a "methylene bridge" to the arylguanidine structure, regardless of its functional activity, results in a 5-HT3 receptor antagonist.

  DOI：

  10.1021/acschemneuro.8b00431

文献信息

• Novel guanidinobenzamides
  申请人：——

  公开号：US20020137939A1

  公开（公告）日：2002-09-26

  Compounds of formula IA and IB are new 1 where the variables R 1 through R 10 have the values set forth herein. Such compounds have use in treating diseases such as obesity and type II diabetes, and may be provided as pharmaceutical formulations in conjunction with a pharmaceutically acceptable carrier.

  公式IA和IB的化合物是新的，其中变量R1到R10具有以下数值。这些化合物在治疗肥胖和2型糖尿病等疾病方面具有用途，并可作为与药学上可接受的载体结合的药物制剂提供。
• AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR
  申请人：Codd Ellen

  公开号：US20080097102A1

  公开（公告）日：2008-04-24

  This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to β-aminotetralin-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.

  本发明涉及辣椒素受体VR1配体。更具体地说，本发明涉及β-氨基四氢萘基脲，它们是VR1的有效拮抗剂或激动剂，用于治疗和预防哺乳动物的炎症和其他疼痛症状。
• Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators
  申请人：Flagship Pioneering Innovations V, Inc.

  公开号：US11208475B1

  公开（公告）日：2021-12-28

  The present invention provides methods for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators, such as serotonin receptor activating antibodies, among others. The invention also features compositions containing serotonin receptor activators, methods of diagnosing patients with a serotonin receptor-associated inflammatory or autoimmune disease or condition, and methods of predicting the response of an inflammatory or autoimmune disease or condition in a subject to treatment with serotonin receptor activators.

  本发明提供了使用血清素受体激活剂（如血清素受体激活抗体等）治疗炎症性或自身免疫性疾病或病症的方法。本发明还包括含有血清素受体激活剂的组合物、诊断与血清素受体相关的炎症或自身免疫性疾病或病症患者的方法，以及预测受试者的炎症或自身免疫性疾病或病症对血清素受体激活剂治疗的反应的方法。
• Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting <i>Plasmodium falciparum</i> Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity
  作者：Sreekanth Kokkonda、Xiaoyi Deng、Karen L. White、Jose M. Coteron、Maria Marco、Laura de las Heras、John White、Farah El Mazouni、Diana R. Tomchick、Krishne Manjalanagara、Kakali Rani Rudra、Gong Chen、Julia Morizzi、Eileen Ryan、Werner Kaminsky、Didier Leroy、María Santos Martínez-Martínez、Maria Belen Jimenez-Diaz、Santiago Ferrer Bazaga、Iñigo Angulo-Barturen、David Waterson、Jeremy N. Burrows、Dave Matthews、Susan A. Charman、Margaret A. Phillips、Pradipsinh K. Rathod

  DOI：10.1021/acs.jmedchem.6b00275

  日期：2016.6.9

  Malaria persists as one of the most devastating global infectious diseases. The pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH) has been identified as a new malaria drug target, and a triazolopyrimidine-based DHODH inhibitor I (DSM265) is in clinical development. We sought to identify compounds with higher potency against Plasmodium DHODH while showing greater selectivity toward animal DHODHs. Herein we describe a series of novel triazolopyrimidines wherein the p-SF5-aniline was replaced with substituted 1,2,3,4-tetrahydro-2-naphthyl or 2-indanyl amines. These compounds showed strong species selectivity, and several highly potent tetrahydro-2-naphthyl derivatives were identified. Compounds with halogen substitutions displayed sustained plasma levels after oral dosing in rodents leading to efficacy in the P. falciparum SCID mouse malaria model. These data suggest that tetrahydro-2-naphthyl derivatives have the potential to be efficacious for the treatment of malaria, but due to higher metabolic clearance than 1, they most likely would need to be part of a multidose regimen.
• GUANIDINOBENZAMIDES AS MC4-R AGONISTS
  申请人：CHIRON CORPORATION

  公开号：EP1409468A2

  公开（公告）日：2004-04-21